NCT06653322Active, not recruitingPhase 3
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
Guangdong Hengrui Pharmaceutical Co., Ltd1 site in 1 country401 target enrollmentStarted: November 21, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 401
- Locations
- 1
- Primary Endpoint
- Annualised asthma exacerbation rate，about 48weeks
Study Overview
Brief Summary
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 12 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •At least 12 years of age
- •A minimum weight of 40kg
- •A medical history of at least 1 year that meets the diagnosis of asthma;
- •Current treatment with medium- or high- doses of ICS for at least 6 months and using steadily at least 3 months
- •Current treatment with an additional controller medication, besides ICS, for at least 3 months and using steadily at least 1 month
- •Absolute count of blood eosinophils suggests eosinophilic asthma
- •During the screening period and baseline, pre- BD FEV1% < 80%
- •During the screening period and baseline, ACQ-6 score indicates asthma poor control
- •History of severe asthma exacerbation within the past 12 months prior to screening
- •Good compliance with eDiary completion
- •Take efficient contraceptive measures
- •Voluntarily sign the informed consent form to participate in this study
Exclusion Criteria
- •With other condition that could lead to elevated eosinophils
- •With Clinically significant pulmonary diseases
- •With existing immunodeficiency disease
- •With other clinically significant diseases that may affect lung function
- •With uncontrolled severe cardiovascular and cerebrovascular diseases
- •With uncontrolled hypertension and/or diabetes
- •With exacerbation, allergic rhinitis or sinusitis attacks, or clinical significant infection requiring intervention during 4 weeks prior to randomization
- •Recent major surgeries or surgical plans during the study period, or treatment measures that investigators believe may affect subject evaluation
- •Existing parasitic infections
- •Diagnosed as malignant tumor within the first 5 years of randomization
- •Significant abnormalities in screening period or baseline laboratory tests
- •Screening period or baseline ECG QTc prolongation
- •Prohibited drugs using during the pre randomization period
- •Participated in other clinical trials within 30 days prior to screening and used research drugs containing active ingredients, or was still within 5 half lives of the research drug at the time of screening
- •Smoking or quitting smoking for less than 6 months during screening, or previous smoking history ≥ 10 pack years
- •History of drug use, alcoholism, or substance abuse within the past year prior to screening
- •Allergic or intolerant to IL-5 monoclonal antibodies or other biological agents
- •Pregnant or lactating subjects
- •Other reasons why the researcher deemed it unsuitable for conducting this experiment
Arms & Interventions
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Subjects receiving SHR-1703 dose 1
Experimental
Intervention: HR-1703 (Drug)
Outcomes
Primary Outcomes
Annualised asthma exacerbation rate，about 48weeks
Time Frame: about 48weeks
Secondary Outcomes
- Mean number of days with oral corticosteroids taken for exacerbation，about 48weeks(about 48weeks)
- Frequency of exacerbations requiring hospitalisation，about 48weeks(about 48weeks)
- Time to first exacerbation requiring hospitalisation，about 48weeks(about 48weeks)
- Mean change from baseline in clinic pre- and post-BD FEV1，about 64 weeks(about 64 weeks)
- Mean change from baseline in clinic pre- and post-BD FEV1%，about 64weeks(about 64weeks)
- Mean change from baseline in clinic pre- and post-BD FVC，about 64 weeks(about 64 weeks)
- Mean change from baseline in clinic pre- and post-BD PEF，about 64 weeks(about 64 weeks)
- Mean change from baseline in FeNO，about 64weeks(about 64weeks)
- Mean change from baseline in asthma control questionnaire (ACQ-6) score，about 64 weeks(about 64 weeks)
- Mean change from baseline in ASTHMA QUALITY OF LIFE QUESTIONNAIRES (AQLQ) score，about 64weeks(about 64weeks)
- Mean change from baseline in Asthma symptom score at week 12/24/36/48/60，about 64weeks(at week 12/24/36/48/60，about 64weeks)
- Mean change from baseline in daily rescue medication use at week 12/24/36/48/60，about 64weeks(at week 12/24/36/48/60，about 64weeks)
- Mean change from baseline in awakening at night due to asthma symptoms requiring rescue medication use at week 12/24/36/48/60，about 64weeks(at week 12/24/36/48/60，about 64weeks)
- Mean change from baseline in morning and evening PEF at week 12/24/36/48/60，about 64weeks(at week 12/24/36/48/60，about 64weeks)
- Mean change from baseline in IgE，about 64weeks(about 64weeks)
- Adverse events，about 64weeks(about 64weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil PhenotypeAsthma With Eosinophilic PhenotypeNCT05522439Jiangsu HengRui Medicine Co., Ltd.85
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）Eosinophilic Granulomatosis With PolyangiitisNCT05979051Guangdong Hengrui Pharmaceutical Co., Ltd166
Completed
Phase 1
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's DiseaseAlzheimer's Disease (AD)NCT06114745Atridia Pty Ltd.2
Recruiting
Phase 3
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenHER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaNCT06123494Jiangsu HengRui Medicine Co., Ltd.360
Completed
Phase 1
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's DiseaseAlzheimer's DiseaseNCT05681819Shanghai Hengrui Pharmaceutical Co., Ltd.33